KNSA.NASDAQ
- Kiniksa Pharmaceuticals International plc
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.24/--
|
企业价值
1.96B
|
资产负债 |
每股账面净值
6.27
|
现金流量 |
现金流量率
0.02
|
损益表 |
收益
423.24M
|
每股收益
3.41
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |